Indication
HER2 Low Breast Neoplasms
1 clinical trial
2 products
Clinical trial
A Phase 1b/2 Open-Label Study of Disitamab Vedotin Monotherapy or in Combination With Other Anticancer Therapies in Solid TumorsStatus: Recruiting, Estimated PCD: 2030-01-31
Product
Disitamab vedotinProduct
tucatinib